Phathom Pharmaceuticals Inc

PHATNASDAQ · USD
7.48USD0.00 (-3.49%)
235

Phathom Pharmaceuticals Inc (PHAT) Covered Calls

As of September 18, 2026, PHAT has 6 covered call opportunities in the coming three months. Return ranges from 1.6 to 55.1% until expiration. Annualized return ranges from 3.8 to 52.2%. The nearest expiration is January 15, 2027. Maximum potential profit is $412.

Read more

Running PHAT covered calls helps you generate consistent income from Phathom Pharmaceuticals Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Phathom Pharmaceuticals Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best PHAT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if PHAT stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling PHAT covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Phathom Pharmaceuticals Inc covered call is worth writing.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Income-focused investors, long-term PHAT holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling PHAT covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Phathom Pharmaceuticals Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile9.13% Subdued
  • Market cap (M$)605
  • 52 weeks high-59.15%
  • 52 weeks low0.27%
  • Analyst recommendationStrong Buy
    1.45
  • Target price$20.45
    173.40% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-10-29
  • P/E
  • Future P/E9.59
  • EPS (ttm)-1.27
  • EPS growth next 5 years

As of September 18, 2026

2027-05-2124510.0033.690.104.90262.0035.0352.18-1.34+0.6204.80
2028-01-2149010.0033.691.605.40412.0055.0841.03-21.39+0.71123.80
2028-01-214907.500.272.604.10262.0035.0326.09-34.76+0.738,0111.50
2027-05-212457.500.271.253.50127.0016.9825.29-16.71+0.6702.25
2027-01-151197.500.270.154.8017.002.276.97-2.01+0.67314.65
2027-02-191547.500.270.104.9012.001.603.80-1.34+0.6704.80

As of September 18, 2026

Sell covered calls with the data behind you

Find the best PHAT covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial